MGNX shows severe financial deterioration with cash declining 69% to $57.2M, stockholders equity falling 52%, and total liabilities increasing 38% despite improved operating performance.
The dramatic cash burn and equity erosion signal potential liquidity concerns for this clinical-stage biotech, especially given the negative operating cash flow of $81M annually. While the company improved operating losses and reduced R&D spending, the balance sheet deterioration suggests potential financing needs or strategic pressures ahead.
MGNX's financial position weakened substantially with cash dropping from $182.8M to $57.2M and stockholders equity falling by half to $55.6M, while total liabilities jumped 38% to $201.3M. Despite operational improvements including a 34% reduction in operating losses and 17% cut in R&D expenses, the company continues burning $81M annually in operating cash flow. The combination of rapid cash depletion, eroding equity base, and rising liabilities creates a concerning liquidity picture that may require near-term financing solutions.
Receivables surged 210.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Cash declined 68.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Capex reduced 48.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities grew 38.2% — significant increase in debt or obligations, assess impact on financial flexibility.
Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.
Current liabilities reduced — improved short-term financial position and working capital health.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
R&D spending cut 16.9% — could signal cost discipline or concerning reduction in innovation investment.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →